A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...
An update from Vivani Medical ( (VANI) ) is now available. Vivani Medical is advancing its innovative GLP-1 implant technology to address ...
Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production ...
Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...
Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases ...
Interestingly, the GLP-1 pathway affects the gastrointestinal [GI] system and ... Fat loss without considerable muscle loss ...
In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...
As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...
A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...
"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...
Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback